JP2024538595A - セリアック病エピトープ - Google Patents

セリアック病エピトープ Download PDF

Info

Publication number
JP2024538595A
JP2024538595A JP2024519079A JP2024519079A JP2024538595A JP 2024538595 A JP2024538595 A JP 2024538595A JP 2024519079 A JP2024519079 A JP 2024519079A JP 2024519079 A JP2024519079 A JP 2024519079A JP 2024538595 A JP2024538595 A JP 2024538595A
Authority
JP
Japan
Prior art keywords
peptide
seq
cell
epitope
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538595A5 (https=
Inventor
ゲール オーゲ レゼット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nextera AS
Original Assignee
Nextera AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextera AS filed Critical Nextera AS
Publication of JP2024538595A publication Critical patent/JP2024538595A/ja
Publication of JP2024538595A5 publication Critical patent/JP2024538595A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024519079A 2021-09-28 2022-09-28 セリアック病エピトープ Pending JP2024538595A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2113858.1A GB202113858D0 (en) 2021-09-28 2021-09-28 Peptides
GB2113858.1 2021-09-28
PCT/GB2022/052450 WO2023052759A1 (en) 2021-09-28 2022-09-28 Celiac disease epitopes

Publications (2)

Publication Number Publication Date
JP2024538595A true JP2024538595A (ja) 2024-10-23
JP2024538595A5 JP2024538595A5 (https=) 2025-10-06

Family

ID=78399559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519079A Pending JP2024538595A (ja) 2021-09-28 2022-09-28 セリアック病エピトープ

Country Status (6)

Country Link
US (1) US20240400692A1 (https=)
EP (1) EP4408539A1 (https=)
JP (1) JP2024538595A (https=)
CA (1) CA3233346A1 (https=)
GB (1) GB202113858D0 (https=)
WO (1) WO2023052759A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
JP7420330B2 (ja) * 2019-06-13 2024-01-23 学校法人藤田学園 アレルギーの抗原およびそのエピトープ
JP2023500799A (ja) * 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Ｃａｌ－ｔコンストラクトおよびその使用

Also Published As

Publication number Publication date
GB202113858D0 (en) 2021-11-10
WO2023052759A1 (en) 2023-04-06
CA3233346A1 (en) 2023-04-06
US20240400692A1 (en) 2024-12-05
EP4408539A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
AU2021282532B2 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
US20230083931A1 (en) Coronavirus vaccines and methods of use
Mézière et al. In vivo T helper cell response to retro-inverso peptidomimetics
CN102438643B (zh) 用于治疗乳糜泻的组合物和方法
Candia et al. On peptides and altered peptide ligands: from origin, mode of action and design to clinical application (immunotherapy)
JP2023515386A (ja) 制御性ｔ細胞エピトープと脱寛容化ｓａｒｓ－ｃｏｖ－２抗原
TW201833137A (zh) 靶向ｃｄ１２７之抗體和多肽
EP1560847A2 (en) Acetylated hmgb1 protein
US20170232083A1 (en) Methods of diagnosis and treatment of celiac disease in children
PT1835937E (pt) Composições e métodos para tratar infeção viral
US20240117020A1 (en) Hypoallergenic peanut allergens, production and use thereof
Tye-Din et al. Immunopathogenesis of celiac disease
WO2021107775A1 (en) Teipp peptide variant and uses thereof
US12226449B2 (en) Materials and methods for the prevention of rheumatoid arthritis
JP2024538595A (ja) セリアック病エピトープ
AU2011330906A1 (en) Cross protective epitopes of aspergillus fumigatus and candida albicans
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
Szabados et al. Characterization of desmoglein‐3 epitope region peptides as synthetic antigens: analysis of their in vitro T cell stimulating efficacy, cytotoxicity, stability, and their conformational features
Charles Identification of B and T cell epitopes using recombinant proteins
Binding et al. Modification of MHC Anchor
CN114630837A (zh) 抗原性多肽及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250925